# Pharma.AI

Type: Technology

Source: AI Intelligence Brief — https://getaibrief.com/entity/pharmaai
Canonical HTML page: https://getaibrief.com/entity/pharmaai

## Timeline

- **2026-06-22**: Collaboration Announced at BIO 2026 — Insilico Medicine and SK Biopharmaceuticals announced a research and development collaboration, value up to $2.5 billion, to discover AI‑enabled drug candidates for neuroimmune disorders of the CNS.

## Recent coverage (1 stories)

### $2.5B Partnership: Generative AI Platform Captures Largest CNS Drug Deal
2026-06-23 04:57:18 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

Insilico Medicine's Pharma.AI generative AI platform landed a record $2.5B collaboration with SK Biopharmaceuticals to design and optimize therapeutics for neuroimmune disorders. The deal, announced at BIO 2026, represents the largest validation of an end‑to‑end AI drug discovery engine in the CNS space, proving that generative modeling can transcend oncology and infuse new life into neurology pipelines.
Full story: https://getaibrief.com/story/generative-ai-drug-discovery-pharma-ai-platform-2-5b-skb

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getaibrief.com/guides/methodology for the full editorial methodology.